Seasonal distribution of COPD exacerbations in the prevention of exacerbations with tiotropium in COPD trial

Chest

Volumn 143, Issue 3, 2013, Pages 711-719

  Rabe, Klaus F ^a   Fabbri, Leonardo M ^b   Vogelmeier, Claus ^c   Kögler, Harald ^d   Schmidt, Hendrik ^d   Beeh, Kai M ^e   Glaab, Thomas ^d  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e Institut fur Atemwegsforschung INSAF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARDIOVASCULAR AGENT; CORTICOSTEROID; SALMETEROL; TIOTROPIUM BROMIDE;

2009 H1N1 INFLUENZA; ADULT; AGE; AGED; ANTIBIOTIC THERAPY; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; GENDER; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PANDEMIC; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEASONAL VARIATION; SMOKING;

EID: 84874997685     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1277     Document Type: Article

References (35)

1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease revised 2011. Global Initiative for Chronic Obstructive Lung Disease website. http://www.goldcopd.org. Accessed February 12, 2012.
2. National Institute for Health and Clinical Excellence. Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. London, England: National Clinical Guideline Centre; 2010.
3. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60 (11): 925-931.
4. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007; 370 (9589): 786-796.
5. Donaldson GC, Wedzicha JA. COPD exacerbations. 1: Epidemiology. Thorax. 2006; 61 (2): 164-168.
6. Donaldson GC, Goldring JJ, Wedzicha JA. Influence of season on exacerbation characteristics in patients with COPD. Chest. 2012; 141 (1): 94-100.
7. Hurst JR, Donaldson GC, Wilkinson TM, Perera WR, Wedzicha JA. Epidemiological relationships between the common cold and exacerbation frequency in COPD. Eur Respir J. 2005; 26 (5): 846-852.
8. Jenkins CR, Celli B, Anderson JA, et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J. 2012; 39 (1): 38-45.
9. Miravitlles M, Ferrer M, Pont A, et al IMPAC Study Group. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004; 59 (5): 387-395.
10. Vogelmeier C, Hederer B, Glaab T, et al; POET-COPD Investi gators. Tiotropium versus salmeterol for the prevenion of exac erbations of COPD. N Engl J Med. 2011; 364 (12): 1093-1103.
11. Danet S, Richard F, Montaye M, et al. Unhealthy effects of atmospheric temperature and pressure on the occurrence of myocardial infarction and coronary deaths. A 10-year survey: the Lille-World Health Organization MONICA project (Monitoring trends and determinants in cardiovascular disease). Circulation. 1999; 100 (1): E1 - E7.
12. Spencer FA, Goldberg RJ, Becker RC, Gore JM. Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction. J Am Coll Cardiol. 1998; 31 (6): 1226-1233.
13. Calverley PM, Anderson JA, Celli B, et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356 (8): 775-789.
14. Johnston NW. The similarities and differences of epidemic cycles of chronic obstructive pulmonary disease and asthma exacerbations. Proc Am Thorac Soc. 2007; 4 (8): 591-596.
15. Johnston NW, McIvor A, Lambert K, et al. The Christmas season as a risk factor for chronic obstructive pulmonary disease exacerbations. Can Respir J. 2010; 17 (6): 275-281.
16. Donaldson GC, Seemungal T, Jeffries DJ, Wedzicha JA. Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. Eur Respir J. 1999; 13 (4): 844-849.
17. Dowell SF. Seasonal variation in host susceptibility and cycles of certain infectious diseases. Emerg Infect Dis. 2001; 7 (3): 369-374.
18. Eccles R. An explanation for the seasonality of acute upper respiratory tract viral infections. Acta Otolaryngol. 2002; 122 (2): 183-191.
19. Peacock JL, Anderson HR, Bremner SA, et al. Outdoor air pollution and respiratory health in patients with COPD. Thorax. 2011; 66 (7): 591-596.
20. Janssens W, Mathieu C, Boonen S, Decramer M. Vitamin D deficiency and chronic obstructive pulmonary disease: a vicious circle. Vitam Horm. 2011; 86 : 379-399.
21. Zosky GR, Berry LJ, Elliot JG, James AL, Gorman S, Hart PH. Vitamin D deficiency causes deficits in lung function and alters lung structure. Am J Respir Crit Care Med. 2011; 183 (10): 1336-1343.
22. Ampikaipakan SN, Hughes DA, Hughes JC, Amen T, Bentham G, Wilson AM. Vitamin D and COPD: seasonal variation is important. Thorax. 2011; 66 (6): 541-542.
23. Kunisaki KM, Niewoehner DE, Connett JE; COPD Clinical Research Network. Vitamin D levels and risk of acute exacerbations of chronic obstructive pulmonary disease: a prospective cohort study. Am J Respir Crit Care Med. 2012; 185 (3): 286-290.
24. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006; 173 (10): 1114-1121.
25. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 164 (9): 1618-1623.
26. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008; 359 (22): 2355-2365.
27. Wedzicha JA. Role of viruses in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004; 1 (2): 115- 120.
28. Wilkinson TM, Hurst JR, Perera WR, Wilks M, Donaldson GC, Wedzicha JA. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest. 2006; 129 (2): 317-324.
29. Wang KY, Seed P, Schofield P, Ibrahim S, Ashworth M. Which practices are high antibiotic prescribers? A crosssectional analysis. Br J Gen Pract. 2009; 59 (567): e315 - e320.
30. Wedzicha JA. Choice of bronchodilator therapy for patients with COPD. N Engl J Med. 2011; 364 (12): 1167-1168.
31. Hurst JR, Donaldson GC, Quint JK, Goldring JJ, Baghai- Ravary R, Wedzicha JA. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 179 (5): 369-374.
32. Roberts CM, Lowe D, Bucknall CE, Ryland I, Kelly Y, Pearson MG. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2002; 57 (2): 137-141.
33. Poland GA. The 2009-2010 influenza pandemic: effects on pandemic and seasonal vaccine uptake and lessons learned for seasonal vaccination campaigns. Vaccine. 2010; 28 (Suppl 4): D3 - D13.
34. Sullivan SJ, Jacobson RM, Dowdle WR, Poland GA. 2009 H1N1 influenza. Mayo Clin Proc. 2010; 85 (1): 64-76.
35. Bautista E, Chotpitayasunondh T, Gao Z, et al Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010; 362 (18): 1708-1719.